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Introduction
Ischemic cerebrovascular disease leads to approximately 6 million deaths every year worldwide [1] . In addition to neurological damage, other important causes of mortality from ischemic cerebrovascular disease are cardiac dysfunction and myocardial damage during the initial period of cerebral ischemia [2, 3] . Tremendous progress has been made in understanding the pathophysiology of strokes; however, effective therapies are still lacking for stroke patients, and the approved stroke therapy is limited by its narrow time window for application [4, 5] . Recently, antioxidant treatments have begun to be investigated as potential stroke therapeutics. Increasing evidence has demonstrated that reactive oxygen species (ROS) contribute to ischemic injury. Although the sources for and mechanisms of ROS generation during ischemia remain elusive, evidence from studies using antioxidants or ROS-overproduction approaches have demonstrated the central roles of ROS in cell death signaling pathways [6, 7] and have determined that cell death plays a critical role in ischemic injury.
Apoptosis and autophagy are two major pathways of cell death. Apoptosis is regulated by Bcl-2 family proteins [8, 9] . The delayed neuronal death caused by ischemia has been attributed to apoptosis, which has been intensively studied. Recently, autophagy has also been determined to be crucial in the process of cellular apoptosis. Autophagy is an active response to various stresses in the body that eliminates damaged structures [10] . Autophagy prevents cells from undergoing apoptosis by degrading damaged mitochondria [11] . Resveratrol has been associated with increased autophagy in certain diseases [12, 13] .
Resveratrol (3,4',5-trihydroxy-trans-stilbene ) is a unique antioxidant and antibrain trauma in animal models and is being tested in clinical trials [15, 16] . Numerous studies have revealed that mitochondria are central to the pathogenesis of stroke and other neurodegenerative diseases [17, 18] . Previous studies have demonstrated that resveratrol and brain [19, 20] . However, the molecular mechanisms underlying the neuroprotective effects of resveratrol are not fully understood. The protective mechanism of action of resveratrol in rats with cerebral ischemia, we aimed to determine whether resveratrol administration before MCAO could reduce ischemia-induced brain and myocardial injuries by regulating apoptosis and autophagy.
Materials and Methods

Animals and Experimental Protocols
Healthy male Wistar rats (3-4 months old, 250 ± 20 g) were used in this study. All the rats were housed at the animal facility with a room temperature of 23 ± 1°C, 55 ± 5% humidity, and a 12 h dark/light cycle and were allowed unlimited food and water. The animals were fasted overnight before the experiment. All the University, China.
The rats were randomly divided into four groups: sham operation (Sham, n = 70), MCAO (MCAO, n = 90), resveratrol-treated MCAO (Res, n =90) and vehicle-treated MCAO (Veh, n = 90). Resveratrol (SigmaAldrich) was freshly prepared in 50% ethanol [15] . The rats were intraperitoneally injected with 30 mg/kg resveratrol once a day for 7 days before surgery and 30 min before inducing ischemia, with the volume not exceeding 0.1 ml/100 g body weight. The resveratrol dose and the treatment protocol were selected based on previous reports that demonstrated the antioxidant property of resveratrol in different experimental models at doses ranging from 8-40 mg/kg [21, 22] .
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Cerebral Ischemia Induced by Middle Cerebral Artery Occlusion
The operating procedure for occluding the middle cerebral artery has been previously described [23] .
thread (diameter 0.28 mm) was inserted from the external carotid artery to the right internal carotid artery (17.5 ± 0.5 mm) to occlude the origin of the right middle cerebral artery (MCA) for 24 h. In sham-operated rats, the thread was removed as soon as the origin of the MCA was reached.
Measurements of Hemodynamic Function of the heart
Hemodynamic function was assessed 24 h after the MCAO operation. The left ventricular end diastolic were measured during contraction (+dP/dt) and relaxation (-dP/dt) using a polygraph as described previously [24] .
Measurement of Cerebral Infarct Volume
and cut into 2 mm thick coronal slices. The infarct volume was determined by TTC staining as previously described [25, 26] . The brain slices were evaluated by an investigator who was blinded to the treatment.
the infarct volume by the total volume of the sections.
Detection of SOD and MDA in the Hippocampus
using assay kits (Nanjing Jiancheng Biotechnology Co., Nanjing, China) according to the manufacturers' was added to a test tube and heated in boiling water for 40 min. The solution was then cooled, and the
TUNEL Staining for Neuronal Apoptosis in the Hippocampus
for 15 min and then quenched for 10 min in 3% hydrogen peroxide at room temperature. After three 10
were washed in PBS three times for 10 min each, and then color development was performed in the dark mm length of the medial CA1 pyramidal cell layer was carefully counted in three sections per animal. The hippocampal cell counts for each of the three sections were averaged to obtain the mean value.
Western Blotting
Total protein samples were extracted from the hippocampus using previously described procedures was then separately incubated with a rabbit polyclonal anti-Bax (Cell Signaling Technology, MA, USA), anti- tetroxide for 1 h. The blocks were then dehydrated in an ethanol series, and slices were cut with an ultrathin Japan).
Mitochondrial Membrane Potential in Neurons and Cardiomyocytes
isolated from fresh hippocampal tissue and left ventricular muscle using a tissue mitochondrial isolation kit (Beyotime, China). Next, 0.1 ml of the isolated mitochondrial protein (40 μg) was incubated with 0.9 ml ex em ex em in each treatment group was calculated as the ratio of aggregates to monomers.
LDH and CK Release Assay
At 24 h post-MCAO, blood samples were collected from the ventral aorta and were centrifuged at 3000 g for 10 min to isolate the serum. Myocardial cellular damage was evaluated by measuring lactate (Nanjing Jiancheng Biotechnology Co., Nanjing, China).
Data Analysis and Statistics
the Turkey test was used for multiple comparisons. A two-tailed value of p<0.05 was considered to be
Results
Resveratrol exhibited a critical protective effect against cerebral ischemic damage in vivo
To determine whether resveratrol protected against cerebral ischemic damage in vivo, we performed survival experiments as an independent preliminary experiment. The treated rats started dying at 5 h. In the MCAO group, the death rate was 20% (4/20) within 6 h, 35% (7/20) within 24 h and 45% (9/20) within 48 h after MCAO. In the resveratrol pretreatment group, the death rate was 5% (1/20) within 6 h, 15% (3/20) within 24 h and 15% (3/20) within 48 h after MCAO. These results indicated that resveratrol was essential for prolonging survival after MCAO.
Neuroprotective effect of resveratrol against ischemia-induced brain injury
After rats were subjected to 24 h of cerebral ischemia in the stroke model, the than the resveratrol-treated rats. The average neurological score in the MCAO group was morphological characteristics of the brain sections from each group after 2% TTC staining. TTC staining revealed an extensive pale infarct area in the brain sections from rats in the MCAO group, whereas there was no infarct area in the sham-treated animals. Resveratrol and the pro-apoptotic protein Bax are crucial determinants of the apoptotic response. Our data revealed that compared with the MCAO group, the ratio of Bcl-2/Bax in the resveratrol group was increased, and there was no obvious change in the vehicle control group. These the Bcl-2/Bax ratio after ischemia-induced brain injury.
Resveratrol increased autophagy after 24 h of cerebral ischemia
LC3-II is required for the formation of autophagosomes and is a biomarker of autophagosomes in mammalian cells. LC3-II is the cleaved and lipidated form of cytosolic LC3-I. The protein levels of LC3 were determined by Western blotting. Our data indicated an increase in the LC3-II/LC3-I ratio in the MCAO group compared with the sham group. indicated that resveratrol might enhance neuronal autophagy by increasing LC3II expression.
Resveratrol improved the mitochondrial integrity in neurons
Transmission electron microscopy was performed on samples from each group 24 h after cerebral ischemia. The hippocampal structure in the sham group was normal as indicated by the number of mitochondria and the intact appearance of the mitochondrial organelles suffered severe ischemic damage with swollen and fractured structures. In the resveratrol pretreatment group, only a few mitochondria were swollen and a few autophagosomes were observed, but the vehicle group exhibited no protective effect against ischemic damage. These data implied that resveratrol pretreatment protected mitochondria from structural damage in response to cerebral ischemia. that resveratrol might be involved in protecting mitochondria during myocardial damage induced by MCAO. Hemodynamic parameters were also measured in the four groups of rats. Our observations suggested that resveratrol pretreatment attenuated cardiac contractile dysfunction in cerebral ischemic rats, which was supported by the increase in LVSP and ±dP/ In summary, resveratrol is a unique compound that protected against neurological and related cardiovascular damage induced by experimental stroke through multiple mechanisms, including decreasing oxidative damage and apoptosis and regulating mitochondria. These data suggested that resveratrol is a promising neuroprotective and cardioprotective therapeutic for cerebral ischemia. However, the detailed molecular interactions between resveratrol and mitochondrial proteins remain to be elucidated, and identifying these interactions will be mitochondria-targeted therapeutics against stroke and related myocardial injury.
